Reference health

Executive Summary

https://doi.org/10.1016/j.chest.2021.07.056
CiteStamped reference-health badge
26/26 checkable references clean · checked 2026-08-10

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 26 checked references that resolve
resolves10.1378/chest.11-2301
Antithrombotic Therapy for VTE Disease
resolves10.1016/j.chest.2015.11.026
Antithrombotic Therapy for VTE Disease
resolves10.1378/chest.14-0824
Methodologies for the Development of CHEST Guidelines and Expert Panel Reports
resolves10.1111/jth.13336
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
resolves10.1182/bloodadvances.2018024893
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
resolves10.1093/eurheartj/ehz405
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
resolves10.1111/jth.13172
Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients
resolves10.1016/j.jclinepi.2012.03.013
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
resolves10.1007/s11239-015-1308-1
Guidance for the management of venous thrombosis in unusual sites
resolves10.1161/STR.0000000000000024
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
resolves10.1177/0268355519835618
Catheter-directed thrombolysis vs. anticoagulation for the prevention and treatment of post-thrombotic syndrome in deep vein thrombosis: An updated systematic review and meta-analysis of randomized trials
resolves10.1007/s11239-015-1318-z
Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism
resolves10.1056/NEJMoa1302097
Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism
resolves10.1111/jth.13564
Inferior vena cava filters
resolves10.7326/M18-1206
Increasing Safe Outpatient Management of Emergency Department Patients With Pulmonary Embolism
resolves10.1007/s11239-015-1317-0
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
resolves10.1002/rth2.12102
Managing thrombosis in cancer patients
resolves10.6004/jnccn.2018.0084
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
resolves10.1007/s11239-015-1313-4
Guidance for the prevention and treatment of cancer-associated venous thromboembolism
resolves10.1016/S1470-2045(19)30336-5
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
resolves10.1111/jth.14935
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
resolves10.1177/0961203320950461
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
resolves10.1182/asheducation-2017.1.223
Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis
resolves10.1016/S2352-3026(17)30014-5
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial
resolves10.1182/bloodadvances.2020001830
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
resolves10.1007/s11239-014-1158-2
Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results
The 3 references without a DOI — listed, not checked
no DOI — not checked10.1016/j.chest.2021.07.056_bib6
no DOI — not checkedThrombolysis for acute deep vein thrombosis
no DOI — not checkedHome treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: rationale and design of the HoT-PE trial
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-08-10 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1016/j.chest.2021.07.056"><img src="https://citestamp.com/citestamped/10.1016/j.chest.2021.07.056/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1016/j.chest.2021.07.056/badge.svg)](https://citestamp.com/citestamped/10.1016/j.chest.2021.07.056)